# Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

> **NCT00215943** · PHASE3 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 90 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** zoledronic acid
- **DRUG:** dexamethasone
- **DRUG:** thalidomide
- **DRUG:** vincristine
- **DRUG:** adriamycin

## Key facts

- **NCT ID:** NCT00215943
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215943, "Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00215943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*